EZM2302 (a CARM1 inhibitor) and anti-PD-1 antibody significantly inhibited the immunosuppressive environment in vivo shaped by tumor growth in mice and reduced the efficacy of anti-PD-1 monotherapy in non-small cell lung cancer (80). Here, CARM1 is linked to neoplasm.